[Relationship between the alteration of 6-keto-PGF1 alpha and TXB2 in cervical mucus of patients with threatened preterm labor and the efficacy of magnesium sulfate treatment].
This study was conducted to observe the relationship between the alteration of 6-keto-PGF 1 alpha and TXB2 in cervical mucus of patients with threatened preterm labor and the efficacy of magnesium sulfate treatment, and to examine whether they could act as markers of efficacy and prognosis in treatment of preterm labor. Cervical mucus was collected from 28 patients with threatened preterm labor before and after magnesium sulfate treatment, the levels of 6-keto-PGF1 alpha and TXB2 were determined by radioimmunoassay (RIA). The results showed that the levels of 6-keto-PGF1 alpha and TXB2 decreased in patients successfully treated with magnesium sulfate (P < 0.01), and the ratio of 6-keto-PGF1 alpha to TXB2 increased significantly (P < 0.001). The levels of 6-keto-PGF1 alpha and TXB2 increased in patients with failed magnesium sulfate treatment (P < 0.01), and the relevant ratio decreased significantly (P < 0.001). The results indicate that the levels of 6-keto-PGF1 alpha and TXB2 in the cervical mucus of patients with threatened preterm labor may change significantly before and after magnesium sulfate treatment and they could be used as markers of efficacy and prognosis in treatment of preterm labor.
Zeng
W
W
Department of Obstetrics and Gynecology, Second Affiliated Hospital, WCUMS, Chengdu 610041.
Zhang
M
M
D015121:6-Ketoprostaglandin F1 alpha / Q000378:metabolism*; D000328:Adult; D002582:Cervix Mucus / Q000378:metabolism*; D005260:Female; D006801:Humans; D008278:Magnesium Sulfate / Q000627:therapeutic use*; D007752:Obstetric Labor, Premature / Q000188:drug therapy*; D011247:Pregnancy; D013929:Thromboxane B2 / Q000378:metabolism*; D015149:Tocolytic Agents / Q000627:therapeutic use*
D015149:Tocolytic Agents; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha; D008278:Magnesium Sulfate